These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 36596779)
1. Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial. Kaabi NA; Yang YK; Liang Y; Xu K; Zhang XF; Kang Y; Jin YQ; Hou JW; Zhang J; Yang T; Hussein S; ElDein MS; Lei ZH; Zhang H; Shao S; Liu ZM; Liu N; Zheng X; Su JG; Yang SS; Cong X; Tan Y; Lei W; Gao XJ; Jiang Z; Wang H; Li M; Mekki HM; Zaher W; Mahmoud S; Zhang X; Qu C; Liu DY; Zhang J; Yang M; Eltantawy I; Xiao P; Shen FJ; Wu JJ; Han ZB; Du LF; Tang F; Chen S; Ma ZJ; Zheng F; Hou YN; Li XY; Li X; Wang ZN; Yin JL; Mao XY; Zhang J; Qu L; Zhang YT; Yang XM; Wu G; Li QM Signal Transduct Target Ther; 2023 Jan; 8(1):20. PubMed ID: 36596779 [TBL] [Abstract][Full Text] [Related]
2. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial. Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC; Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Kaabi NA; Yang YK; Du LF; Xu K; Shao S; Liang Y; Kang Y; Su JG; Zhang J; Yang T; Hussein S; ElDein MS; Yang SS; Lei W; Gao XJ; Jiang Z; Cong X; Tan Y; Wang H; Li M; Mekki HM; Zaher W; Mahmoud S; Zhang X; Qu C; Liu DY; Zhang J; Yang M; Eltantawy I; Hou JW; Lei ZH; Xiao P; Wang ZN; Yin JL; Mao XY; Zhang J; Qu L; Zhang YT; Yang XM; Wu G; Li QM Nat Commun; 2022 Jun; 13(1):3654. PubMed ID: 35760812 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. Kaabi NA; Yang YK; Zhang J; Xu K; Liang Y; Kang Y; Su JG; Yang T; Hussein S; ElDein MS; Shao S; Yang SS; Lei W; Gao XJ; Jiang Z; Wang H; Li M; Mekki HM; Zaher W; Mahmoud S; Zhang X; Qu C; Liu DY; Zhang J; Yang M; Eltantawy I; Xiao P; Wang ZN; Yin JL; Mao XY; Zhang J; Liu N; Shen FJ; Qu L; Zhang YT; Yang XM; Wu G; Li QM Signal Transduct Target Ther; 2022 Jun; 7(1):172. PubMed ID: 35665745 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial. Hannawi S; Yan L; Saifeldin L; Abuquta A; Alamadi A; Mahmoud SA; Hassan A; Zhang M; Gao C; Chen Y; Gai W; Xie L EClinicalMedicine; 2023 Oct; 64():102195. PubMed ID: 37731938 [TBL] [Abstract][Full Text] [Related]
6. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial. Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial. Erfanpoor S; Banihashemi SR; Mokhbaeralsafa L; Kalantari S; Es-Haghi A; Nofeli M; Rezaei Mokarram A; Sadeghi F; Hajimoradi M; Razaz SH; Taghdiri M; Lotfi M; Khorasani A; Ansarifar A; Masoumi S; Mohazzab A; Filsoof S; Mohseni V; Shahsavan M; Gharavi N; Setarehdan SA; Rabiee MH; Fallah Mehrabadi MH; Solaymani-Dodaran M BMC Med; 2024 Feb; 22(1):78. PubMed ID: 38378570 [TBL] [Abstract][Full Text] [Related]
8. Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2. Mahmoud S; Ganesan S; Al Kaabi N; Naik S; Elavalli S; Gopinath P; Ali AM; Bazzi L; Warren K; Zaher WA; Hosani FA J Clin Virol; 2022 Jun; 150-151():105161. PubMed ID: 35439702 [TBL] [Abstract][Full Text] [Related]
9. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM Elife; 2022 Aug; 11():. PubMed ID: 36004719 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z; EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435 [TBL] [Abstract][Full Text] [Related]
11. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594 [No Abstract] [Full Text] [Related]
12. Immunogenicity Persistence of a Third-Dose Homologous BBIBP-CorV/CoronaVac Boosting Vaccination: A Prospective Open-Label Study. Ren N; Wang Z; Gao S Viral Immunol; 2024; 37(1):16-23. PubMed ID: 38109058 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang W; Zhang W; Li N; Xie Z; Zhu X; Ding L; You W; Zhao Y; Zhao J; Huang L; Shi X; Yang Y; Xu G; Wang W; Liu P; Ma M; Qiao Y; Zhao S; Chai J; Li Q; Fu H; Xu Y; Zheng X; Guo W; Yang X Lancet Infect Dis; 2022 Feb; 22(2):196-208. PubMed ID: 34536349 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study. Huang T; Zhang S; Dai DF; Wang BS; Zhuang L; Huang HT; Wang ZF; Zhao JS; Li QP; Wu SP; Wang X; Zhang WD; Zhao ZH; Li H; Zhang YP; Yang XL; Jiang XY; Gou JB; Hou LH; Gao LD; Feng ZC Lancet Respir Med; 2023 Aug; 11(8):698-708. PubMed ID: 37209700 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial. Hannawi S; Saifeldin L; Abuquta A; Alamadi A; Mahmoud SA; Hassan A; Liu D; Yan L; Xie L EBioMedicine; 2023 Jan; 87():104386. PubMed ID: 36470077 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine. Chansaenroj J; Suntronwong N; Kanokudom S; Assawakosri S; Yorsaeng R; Vichaiwattana P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Thongmee T; Auphimai C; Nilyanimit P; Wanlapakorn N; Sudhinaraset N; Poovorawan Y Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891235 [TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial. Hu J; Liu Y; Liu S; Shu Q; Yang X; Chu K; Qiao Y; Hu Y; Wang K; Pan H Front Immunol; 2023; 14():1241153. PubMed ID: 37799724 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years. Wanlapakorn N; Kanokudom S; Phowatthanasathian H; Chansaenroj J; Suntronwong N; Assawakosri S; Yorsaeng R; Nilyanimit P; Vichaiwattana P; Klinfueng S; Thongmee T; Aeemjinda R; Khanarat N; Srimuan D; Thatsanatorn T; Chantima W; Pakchotanon P; Duangchinda T; Sudhinaraset N; Poovorawan Y J Med Virol; 2023 May; 95(5):e28758. PubMed ID: 37212319 [TBL] [Abstract][Full Text] [Related]
20. Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults. Zhang Y; Yang Y; Qiao N; Wang X; Ding L; Zhu X; Liang Y; Han Z; Liu F; Zhang X; Yang X Front Med; 2022 Feb; 16(1):93-101. PubMed ID: 35122211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]